Integrating proteomics, metabolomics, and molecular docking to elucidate the mechanism of Jiangtang Qingre formula against metabolic dysfunction-associated steatohepatitis
World Journal of Gastroenterology · 28.12.2026 · 32 (48)
DOI: 10.3748/wjg.123033 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 28.12.2026. Verfasst von Li-Juan Zhou und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND As the most popular chronic liver disease in the world, one third of metabolic dysfunction-associated steatotic liver disease cases will progress to metabolic dysfunction-associated steatohepatitis (MASH), yet current therapeutic options remain strikingly limited. Jiangtang Qingre formula (JQF) has shown significant clinical efficacy, but the underlying mechanism of it is still not clear. AIM To elucidate the mechanism by which JQF ameliorates MASH through integrated multi-omics and experimental validation. METHODS The MASH mouse model was constructed using the methionine-choline-deficient diet, and treated with JQF to evaluate its efficacy. Hepatic proteomics and metabolomics were integrated to screen core targets and pathways, and molecular docking was performed to assess the binding affinity between JQF's core components and key targets. Targeted metabolomics quantified these core components in serum, liver, and feces. Finally, the function of key targets was preliminarily validated by quantitative PCR (qPCR)/Western blotting (WB) and small interfering RNA-mediated knockdown in free fatty acids (FFA)-induced AML12 cells. RESULTS JQF alleviated hepatic injury, steatosis, oxidative stress, inflammation, and fibrosis in MASH mice. Multi-omics analysis suggested that JQF may act by regulating arachidonic acid metabolism, and glutathione metabolism, involving multiple targets including Gsta2, Gsta5, Ifi27 L2b, and Lmod3, which were validated by qPCR/WB. Notably, knockdown of Lmod3 partially alleviated FFA-induced AML12 cell injury, an effect further augmented by JQF. Molecular docking confirmed that timosaponins exhibited the strongest binding affinity to these targets. Targeted metabolomics further revealed that timosaponin A III and timosaponin B II were significantly elevated in serum and liver, with timosaponin A III showing the most prominent enrichment in the liver, while sarsasapogenin, as the major secondary metabolite of timosaponins, was detected at high abundance in feces. CONCLUSION JQF ameliorates MASH through multi-target synergistic mechanisms, with Lmod3 identified as a key target and timosaponins as important pharmacologically active substances.
Zitieren
APA
Zhou, L., Wu, J., Wang, H., Han, R., Tang, C., Fang, F., & Zhu, D. (2026). Integrating proteomics, metabolomics, and molecular docking to elucidate the mechanism of Jiangtang Qingre formula against metabolic dysfunction-associated steatohepatitis. World Journal of Gastroenterology, 32(48). https://doi.org/10.3748/wjg.123033
Vancouver
Zhou L, Wu J, Wang H, Han R, Tang C, Fang F, et al. Integrating proteomics, metabolomics, and molecular docking to elucidate the mechanism of Jiangtang Qingre formula against metabolic dysfunction-associated steatohepatitis. World Journal of Gastroenterology. 2026;32(48). doi:10.3748/wjg.123033
BibTeX
@article{Zhou2026,
author = {Zhou, Li-Juan and Wu, Jin-Lin and Wang, Hang and Han, Rui and Tang, Cai and Fang, Fang and Zhu, Dan-Ping},
title = {Integrating proteomics, metabolomics, and molecular docking to elucidate the mechanism of Jiangtang Qingre formula against metabolic dysfunction-associated steatohepatitis},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {48},
doi = {10.3748/wjg.123033}
}
EUVIMED